Clinical trials
Recruiting Carcinoma, Transitional Cell trials in Taiwan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
7 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 7 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alentis Therapeutics AG | 1 |
| Astellas Pharma Global Development, Inc. | 1 |
| AstraZeneca | 1 |
| Daiichi Sankyo | 1 |
| Eli Lilly and Company | 1 |
| Inhibrx Biosciences, Inc | 1 |
| National Taiwan University Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Transitional Cell | 7 |
| Urinary Bladder Neoplasms | 3 |
| Carcinoma | 2 |
| Colorectal Neoplasms | 2 |
| Melanoma | 2 |
| Neoplasms | 2 |
| Neoplasms by Site | 2 |
| Squamous Cell Carcinoma of Head and Neck | 2 |
| Biliary Tract Neoplasms | 1 |
| Carcinoma, Hepatocellular | 1 |
Trials
Showing 1 to 7 of 7. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.